---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-046176"
form_type: "8-K"
ticker: "KYTX"
cik: "0001994702"
company_name: "Kyverna Therapeutics, Inc."
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T04:24:09.382315+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kyverna Therapeutics enters into $50M at-the-market equity offering facility with Jefferies

## Summary
- Agreement with Jefferies LLC allows sale of up to $50M of common stock from time to time.
- Agent compensation set at 3.0% of gross sales price per share sold.
- Company has no obligation to sell any shares under the Sales Agreement.
- Sales will be made under Company's existing shelf registration statement (Form S-3) filed same day.

## SEC filing metadata
- accession: 0000950170-25-046176
- form_type: 8-K
- ticker: KYTX
- cik: 0001994702
- company_name: Kyverna Therapeutics, Inc.
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1994702/000095017025046176/0000950170-25-046176-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1994702/000095017025046176/kytx-20250327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-046176
- JSON: https://secwatch.observer/filing/0000950170-25-046176.json
- Plain text: https://secwatch.observer/filing/0000950170-25-046176.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.